Skip to main content
Corterve
10 Studies Recruiting

Clinical Trials Near Hartford, CT

Find research studies actively recruiting participants near Hartford. Studies are run at established research institutions including Hartford HealthCare and UConn Health.

Top Research Institutions in Hartford

1

Hartford HealthCare

2

UConn Health

Recruiting Studies Near Hartford

#1

Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

RECRUITINGNot SpecifiedMemorial Sloan Kettering Cancer Center

The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have. They want to know how many patients get a transplant and why some patients do get a transplant while others do not. Also they want to explore why some patients elect not to undergo stem cell transplantation, when it is recommended by their physicians.

๐Ÿ“ Hartford, Connecticut๐Ÿ“ New York, New York
#2

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

RECRUITINGPHASE2Giselle Sholler

The purpose of this study is to evaluate the investigational drug, tipifarnib (a pill taken by mouth), in combination with the Food and Drug Administration (FDA) approved drug, naxitimab, administered intravenously (IV; a liquid that continuously goes into your body through a tube that has been placed during a surgery into one of your veins). Naxitamab is FDA approved for pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy, it may not be approved in the type of disease used in this study. The goals of this part of the study are: * Test the safety and tolerability of tipifarnib in combination with naxitimab in participants with cancer * To determine the activity of study treatments chosen based on: * How each participant responds to the study treatment * How long a participant lives without their disease returning/progressing

๐Ÿ“ Little Rock, Arkansas๐Ÿ“ Hartford, Connecticut๐Ÿ“ Miami, Florida
#3

Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others

RECRUITINGNot SpecifiedMichael Shy

This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C). The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window

๐Ÿ“ Los Angeles, California๐Ÿ“ Palo Alto, California๐Ÿ“ Aurora, Colorado
#4

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

RECRUITINGPHASE3Alkermes, Inc.

To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

๐Ÿ“ Dothan, Alabama๐Ÿ“ Little Rock, Arkansas๐Ÿ“ Stanford, California
#5

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVIยฎ (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

RECRUITINGNot SpecifiedTG Therapeutics, Inc.

The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVIยฎ (ublituximab-xiiy) in the real-world setting

๐Ÿ“ Birmingham, Alabama๐Ÿ“ Cullman, Alabama๐Ÿ“ Huntsville, Alabama
#6

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

RECRUITINGPHASE3Janssen Research & Development, LLC

The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

๐Ÿ“ Los Angeles, California๐Ÿ“ Atlanta, Georgia๐Ÿ“ Atlanta, Georgia
#7

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

RECRUITINGPHASE3European Organisation for Research and Treatment of Cancer - EORTC

This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.

๐Ÿ“ Phoenix, Arizona๐Ÿ“ Duarte, California๐Ÿ“ Irvine, California
#8

PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm

RECRUITINGNAKardion Inc

This purpose of this trial is to demonstrate 30 day safety and effectiveness outcomes of the KARDION CORY P4 System in subjects who require hemodynamic support during a high-risk PCI procedure.

๐Ÿ“ Chandler, Arizona๐Ÿ“ Scottsdale, Arizona๐Ÿ“ Little Rock, Arkansas
#9

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

RECRUITINGNANatera, Inc.

The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signateraโ„ข Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test results, participants will either start CDK4/6 inhibitor therapy in addition to hormone therapy or continue hormone therapy with ongoing ctDNA surveillance. This study will compare outcomes to historical controls from the NataLEE trial to determine whether ctDNA-guided timing maintains efficacy while reducing unnecessary treatment. Participants will be followed for up to 9 years with regular blood draws, hormone therapy, imaging as needed, and quality-of-life assessments.

๐Ÿ“ Greenbrae, California๐Ÿ“ Stockton, California๐Ÿ“ Jacksonville, Florida
#10

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

RECRUITINGPHASE3NRG Oncology

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).

๐Ÿ“ Anchorage, Alaska๐Ÿ“ Anchorage, Alaska๐Ÿ“ Anchorage, Alaska

Clinical Trials in Hartford: FAQ

How do I find clinical trials near Hartford?

Corterve aggregates all actively recruiting clinical trials near Hartford, CT from the ClinicalTrials.gov database. Simply browse the listings on this page or take our assessment to find trials that may be relevant.

Does it cost anything to take part in a study?

Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.

What research institutions are located in Hartford?

Hartford is home to several leading research institutions, including Hartford HealthCare, UConn Health. These facilities run clinical trials across Oncology, Neurology, Cardiology, and other therapeutic areas.

Ready to see studies near you?

Take our assessment to see research studies recruiting near Hartford that may be relevant. Study teams decide who joins.

See studies near you